TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Major Shareholder Buys 62,972 Shares

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) major shareholder Equity Ab Frankenius bought 62,972 shares of TriSalus Life Sciences stock in a transaction that occurred on Tuesday, December 17th. The stock was bought at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the acquisition, the insider now directly owns 6,230,748 shares of the company’s stock, valued at $24,736,069.56. The trade was a 1.02 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

TriSalus Life Sciences Stock Performance

TLSI stock opened at $4.05 on Friday. The stock’s 50 day simple moving average is $4.14 and its 200 day simple moving average is $4.92. The company has a market cap of $123.48 million, a P/E ratio of -1.63 and a beta of 0.56. TriSalus Life Sciences, Inc. has a fifty-two week low of $3.50 and a fifty-two week high of $10.42.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of institutional investors have recently modified their holdings of the company. Walleye Capital LLC acquired a new stake in TriSalus Life Sciences in the 3rd quarter valued at $66,000. Virtu Financial LLC bought a new position in shares of TriSalus Life Sciences in the third quarter valued at $92,000. Vestcor Inc acquired a new position in shares of TriSalus Life Sciences during the third quarter valued at about $108,000. MSD Partners L.P. bought a new stake in shares of TriSalus Life Sciences during the third quarter worth about $184,000. Finally, Wolverine Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences in the 2nd quarter worth about $240,000. 2.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TLSI. Canaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Northland Securities initiated coverage on TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target for the company. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Cantor Fitzgerald started coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They set an “overweight” rating and a $10.00 target price for the company. Finally, Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, TriSalus Life Sciences has a consensus rating of “Buy” and an average price target of $11.79.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.